Overview

Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi

Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is an individually randomized, controlled, single blind four arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent preventive treatment with dihydroartemisinin-piperaquine (IPT-DP). Arm 2: Intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) plus chloroquine (CQ) (IPT-SPCQ). Arm 3: Intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) (IPT-SPAQ).Arm 4: Control - students will receive standard of care (no preventive treatment). Outcomes include P. falciparum infection and parasite density, anemia, cognitive function and educational testing, as well as infection prevalence and disease incidence in young children sleeping student's households to assess the impact on transmission.
Phase:
Phase 4
Details
Lead Sponsor:
Liverpool School of Tropical Medicine
Collaborator:
Kamuzu University of Health Sciences
Treatments:
Amodiaquine
Artenimol
Chloroquine
Fanasil, pyrimethamine drug combination
Hydroxychloroquine
Piperaquine
Pyrimethamine
Sulfadoxine